Title

Synthesis towards several potential inhibitors of Anthrax Lethal Factor through organoboron chemistry

Presenter Information

Michael Frank

Document Type

Oral Presentation

Location

SURC Ballroom C/D

Start Date

16-5-2013

End Date

16-5-2013

Abstract

Anthrax is an acute disease caused by infection of active spores from the bacteria Bacillus anthracis. Immediate treatment is required for individuals infected with the bacteria, resulting in a relatively small window of opportunity to prevent death. Bacillus anthracis secretes a toxin composed of three proteins: lethal factor (LF), edema factor (EM), and protective antigen (PA). Current treatments for infection are limited to a window of opportunity which merits a need for new immediate acting inhibitors. This research has developed three novel potential Anthrax LF inhibitors including analogs to be synthesized. Currently, one of the three initial compound pathways has been completed with improvements to the synthetic route during production. The proposed target compounds could potentially serve as a more effective treatment to acute infection caused by Bacillus anthracis.

Poster Number

47

Faculty Mentor(s)

Levente Fabry-Asztalos

Additional Mentoring Department

Chemistry

This document is currently not available here.

Share

COinS
 
May 16th, 8:20 AM May 16th, 10:50 AM

Synthesis towards several potential inhibitors of Anthrax Lethal Factor through organoboron chemistry

SURC Ballroom C/D

Anthrax is an acute disease caused by infection of active spores from the bacteria Bacillus anthracis. Immediate treatment is required for individuals infected with the bacteria, resulting in a relatively small window of opportunity to prevent death. Bacillus anthracis secretes a toxin composed of three proteins: lethal factor (LF), edema factor (EM), and protective antigen (PA). Current treatments for infection are limited to a window of opportunity which merits a need for new immediate acting inhibitors. This research has developed three novel potential Anthrax LF inhibitors including analogs to be synthesized. Currently, one of the three initial compound pathways has been completed with improvements to the synthetic route during production. The proposed target compounds could potentially serve as a more effective treatment to acute infection caused by Bacillus anthracis.